Cargando…

Mitochondrial dysfunction during loss of prohibitin 1 triggers Paneth cell defects and ileitis

OBJECTIVE: Although perturbations in mitochondrial function and structure have been described in the intestinal epithelium of Crohn’s disease and ulcerative colitis patients, the role of epithelial mitochondrial stress in the pathophysiology of inflammatory bowel diseases (IBD) is not well elucidate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jackson, Dakota N, Panopoulos, Marina, Neumann, William L, Turner, Kevin, Cantarel, Brandi L, Thompson-Snipes, LuAnn, Dassopoulos, Themistocles, Feagins, Linda A, Souza, Rhonda F, Mills, Jason C, Blumberg, Richard S, Venuprasad, K, Thompson, Winston E, Theiss, Arianne L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7483170/ https://www.ncbi.nlm.nih.gov/pubmed/32111635 http://dx.doi.org/10.1136/gutjnl-2019-319523

Ejemplares similares

SHIP deficiency causes Crohn's disease-like ileitis
por: Kerr, William G, et al.
Publicado: (2010)

Inner mitochondrial membrane protein Prohibitin 1 mediates Nix-induced, Parkin-independent mitophagy
por: Alula, Kibrom M., et al.
Publicado: (2023)

Mouse Paneth cell antimicrobial function is independent of Nod2
por: Shanahan, Michael T, et al.
Publicado: (2014)

Mitochondrial impairment drives intestinal stem cell transition into dysfunctional Paneth cells predicting Crohn’s disease recurrence
por: Khaloian, Sevana, et al.
Publicado: (2020)

Nuclear partitioning of Prohibitin 1 inhibits Wnt/β-catenin-dependent intestinal tumorigenesis
por: Alula, Kibrom M., et al.
Publicado: (2020)

Prohibitin 1 Modulates Mitochondrial Stress-Related Autophagy in Human Colonic Epithelial Cells
por: Kathiria, Arwa S., et al.
Publicado: (2012)

Targeting Mitochondrial Damage as a Therapeutic for Ileal Crohn’s Disease
por: Alula, Kibrom M., et al.
Publicado: (2021)

Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial
por: Cozijnsen, M A, et al.
Publicado: (2016)

Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial
por: Zoller, Heinz, et al.
Publicado: (2023)

The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies
por: Narula, Neeraj, et al.
Publicado: (2021)

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
por: Cornillie, Freddy, et al.
Publicado: (2014)

A Randomized, Open-Label, Non-Inferiority Study of Intravenous Iron Isomaltoside 1,000 (Monofer) Compared With Oral Iron for Treatment of Anemia in IBD (PROCEED)
por: Reinisch, Walter, et al.
Publicado: (2013)

Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers
por: Roberts, Carol L, et al.
Publicado: (2010)

Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies
por: Sandborn, W. J., et al.
Publicado: (2015)

Population pharmacokinetics‐pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
por: Rosario, M., et al.
Publicado: (2015)

Relapse after withdrawal from anti‐TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta‐analysis
por: Kennedy, N. A., et al.
Publicado: (2016)

Validation of stricture length, duration and obstructive symptoms as predictors for intervention in ileal stricturing Crohn's disease
por: El Ouali, Sara, et al.
Publicado: (2022)

Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease
por: Kiesslich, R, et al.
Publicado: (2011)

Discrepancy between patient‐ and healthcare provider‐reported adverse drug reactions in inflammatory bowel disease patients on biological therapy
por: Thomas, Pepijn W. A., et al.
Publicado: (2021)

Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability
por: Cani, P D, et al.
Publicado: (2009)

Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview
por: Choi, Chang-Ho Ryan, et al.
Publicado: (2015)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study
por: Travis, Simon P L, et al.
Publicado: (2014)

Surgical Rates for Crohn’s Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study
por: Ma, Christopher, et al.
Publicado: (2017)

Colonic mucosa-associated diffusely adherent afaC+ Escherichia coli expressing lpfA and pks are increased in inflammatory bowel disease and colon cancer
por: Prorok-Hamon, Maelle, et al.
Publicado: (2014)

Fungal microbiota dysbiosis in IBD
por: Sokol, Harry, et al.
Publicado: (2017)

Development and initial psychometric validation of a patient-reported outcome measure for Crohn’s perianal fistula: the Crohn’s Anal Fistula Quality of Life (CAF-QoL) scale
por: Adegbola, Samuel O, et al.
Publicado: (2021)

Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool
por: Curtius, Kit, et al.
Publicado: (2022)

Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
por: Panaccione, Remo, et al.
Publicado: (2020)

Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study
por: Choi, Chang-Ho Ryan, et al.
Publicado: (2019)

Long‐term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study
por: Festa, Stefano, et al.
Publicado: (2021)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
por: Travis, Simon P L, et al.
Publicado: (2011)

Smoking and colorectal neoplasia in patients with inflammatory bowel disease: Dose‐effect relationship
por: Wijnands, Anouk M., et al.
Publicado: (2023)

Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease
por: Koelink, Pim J, et al.
Publicado: (2014)

Developing a core outcome set for fistulising perianal Crohn’s disease
por: Sahnan, Kapil, et al.
Publicado: (2019)

Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling
por: Koelink, Pim J, et al.
Publicado: (2020)

Trends in Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative Databases
por: Benchimol, Eric I, et al.
Publicado: (2017)

PICaSSO virtual electronic chromendoscopy accurately reflects combined endoscopic and histological assessment for prediction of clinical outcomes in ulcerative colitis
por: Nardone, Olga Maria, et al.
Publicado: (2022)

Evolutionary history of human colitis-associated colorectal cancer
por: Baker, Ann-Marie, et al.
Publicado: (2019)

Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases
por: Michaudel, Chloé, et al.
Publicado: (2023)

Rural and Urban Residence During Early Life is Associated with Risk of Inflammatory Bowel Disease: A Population-Based Inception and Birth Cohort Study
por: Benchimol, Eric I, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_e3duikc2qs5o4fifpqiuhq4rkl